R. Schreiber
Recente publicaties
-
Magaraggia, I., Di Cesare, F., Alonso, J., Edgar, C. J., Heckman, P., Engler, J., Domingo, S. Z., Pani, L., & Schreiber, R. (2026). Application of the research domain criteria in early-phase clinical development of transdiagnostic neurotherapeutics: A multidisciplinary perspective. Neuroscience Applied, 5, Article 106996. https://doi.org/10.1016/j.nsa.2026.106996Meer informatie over deze publicatie
-
Duller, S., Clarke, G., Herculano-Houzel, S., von Kanel, R., Kirsch, P., Landolt, H.-P., Naschold, B., Reber, S. O., Schreiber, R., Walter, M., & Slavich, G. M. (2025). Everyday stress-induced neurobehavioral dysregulation: therapeutic targets for management with Neurexan. Frontiers in Psychiatry, 16, Article 1577689. https://doi.org/10.3389/fpsyt.2025.1577689Meer informatie over deze publicatie
-
van Veggel, L., Schepers, M., Tiane, A., Kumar, V., Willems, E., Rombaut, B., Noordijk, J., Vangansewinkel, T., Li, A., Wolfs, E., Ozcan, B., Nouboers, E., Moya, P. R., Sauer, D. B., Diliën, H., Hellings, N., Schreiber, R., & Vanmierlo, T. (2025). EAAT3 modulation: A potential novel avenue towards remyelination in multiple sclerosis. Biomedicine & Pharmacotherapy, 186, 117960. Article 117960. https://doi.org/10.1016/j.biopha.2025.117960Meer informatie over deze publicatie
-
Magaraggia, I., Krauskopf, J., Ramaekers, J. G., You, Y., de Nijs, L., Briedé, J. J., & Schreiber, R. (2025). Harnessing brain-derived extracellular vesicles to support RDoC-based drug development. Neuroscience Applied, 4, Article 105406. https://doi.org/10.1016/j.nsa.2024.105406Meer informatie over deze publicatie
-
van Veggel, L., Voets, A. M., Vanmierlo, T., & Schreiber, R. (2024). Insights from an academic endeavor into central nervous system drug discovery. Neural Regeneration Research, 20(6), 1717-1718. https://doi.org/10.4103/NRR.NRR-D-24-00340Meer informatie over deze publicatie
-
Schreiber, R. (2024). Preface to the First Edition. In Modern CNS Drug Discovery: : Novel Therapeutics for Psychiatric and Neurological Diseases: from Target Identification to Regulatory Approval (2 ed., pp. viii-x). Springer.Meer informatie over deze publicatie
-
Schreiber, R. (2024). Preface to the Second Edition. In R. Schreiber (Ed.), Modern CNS Drug Discovery: Novel Therapeutics for Psychiatric and Neurological Diseases: from Target Identification to Regulatory Approval (2 ed., pp. v-vii). Springer.Meer informatie over deze publicatie
-
Schreiber, R. (2024). Connecting the Dots in Translational Neuroscience. In R. Schreiber (Ed.), Modern CNS Drug Discovery: Novel Therapeutics for Psychiatric and Neurological Diseases: from Target Identification to Regulatory Approval (2 ed., pp. 209-213). Springer. https://doi.org/10.1007/978-3-031-61992-2_11Meer informatie over deze publicatie
-
Broy, J., Schreiber, R., & Govers, M. (2024). From Scientists to Innovators for Industry: An European Program Addressing the Workforce Challenge in the Pharma Industry. In R. S. (Ed.), Modern CNS Drug Discovery: Novel Therapeutics for Psychiatric and Neurological Diseases: from Target Identification to Regulatory Approval (2 ed., pp. 31-48). Springer. https://doi.org/10.1007/978-3-031-61992-2_3Meer informatie over deze publicatie
-
Schreiber, R., Govers, M., & Van der Lugt, A. (2024). Innovator, Entrepreneur, Leader: The Tripartite Drug Discovery Neuroscientist. In R. S. (Ed.), Modern CNS Drug Discovery: Novel Therapeutics for Psychiatric and Neurological Diseases: from Target Identification to Regulatory Approval (2 ed., pp. 9-29). Springer. https://doi.org/10.1007/978-3-031-61992-2_2Meer informatie over deze publicatie